AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval
Specifically engineered antibody treats HER2-positive metastatic breast cancer
Read Moreby John Pinching | Jul 19, 2022 | News | 0
Specifically engineered antibody treats HER2-positive metastatic breast cancer
Read Moreby John Pinching | Jun 6, 2022 | News | 0
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer
Read Moreby John Pinching | Apr 26, 2022 | News | 0
Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates
Read Moreby Lucy Parsons | Sep 20, 2021 | News | 0
‘Groundbreaking results’ for the treatment of HER2-positive metastatic breast cancer
Read Moreby Lucy Parsons | Aug 9, 2021 | News | 0
Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer
Read Moreby Lucy Parsons | Apr 20, 2021 | News | 0
Decision is based on results from the Phase II DESTINY-Breast01 trial
Read Moreby Lucy Parsons | Mar 23, 2021 | News | 0
Collaborative agreement will focus on improving detection and diagnosis of AF
Read Moreby Lucy Parsons | Mar 18, 2021 | News | 0
In the UK, over seven million people are affected by cardiovascular disease
Read Moreby Lucy Parsons | Feb 16, 2021 | News | 0
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Read Moreby Lucy Parsons | Jan 29, 2021 | News | 0
Datopotamab deruxtecan and Enhertu were evaluated in non-small cell lung cancer patients
Read Moreby Lucy Parsons | Jan 18, 2021 | News | 0
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Read Moreby Selina McKee | Dec 8, 2020 | News | 0
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
